Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 7
1991 5
1992 3
1993 7
1994 2
1995 2
1996 2
1997 2
1998 1
1999 2
2000 1
2001 2
2002 5
2003 3
2004 3
2005 4
2006 7
2007 3
2008 7
2009 6
2010 11
2011 12
2012 8
2013 14
2014 14
2015 15
2016 15
2017 13
2018 4
2019 11
2020 12
2021 21
2022 6
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum to "Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis." Kidney Int. 2024;105(3):447-449.
Floege J, Jayne DRW, Sanders JF, Tesar V, Balk EM, Gordon CE, Adam G, Tonelli MA, Cheung M, Earley A, Rovin BH. Floege J, et al. Among authors: jayne drw. Kidney Int. 2024 May 8:S0085-2538(24)00267-9. doi: 10.1016/j.kint.2024.04.004. Online ahead of print. Kidney Int. 2024. PMID: 38739060 No abstract available.
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. Among authors: jayne drw. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS).
Fussner LA, Flores-Suárez LF, Cartin-Ceba R, Specks U, Cox PG, Jayne DRW, Merkel PA, Walsh M; PEXIVAS Investigators. Fussner LA, et al. Among authors: jayne drw. Am J Respir Crit Care Med. 2024 May 1;209(9):1141-1151. doi: 10.1164/rccm.202308-1426OC. Am J Respir Crit Care Med. 2024. PMID: 38346237 Clinical Trial.
Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.
Patel NJ, Jayne DRW, Merkel PA, Bekker P, Zhang Y, Yue H, Stone JH. Patel NJ, et al. Among authors: jayne drw. Lancet Rheumatol. 2023 Mar;5(3):e130-e138. doi: 10.1016/S2665-9913(23)00030-9. Epub 2023 Feb 20. Lancet Rheumatol. 2023. PMID: 38251609 Clinical Trial.
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
Strand V, Jayne DRW, Horomanski A, Yue H, Bekker P, Merkel PA; ADVOCATE Study Group. Strand V, et al. Among authors: jayne drw. Lancet Rheumatol. 2023 Aug;5(8):e451-e460. doi: 10.1016/S2665-9913(23)00092-9. Epub 2023 Jul 24. Lancet Rheumatol. 2023. PMID: 38251577 Clinical Trial.
The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial.
Patel NJ, Jayne DRW, Merkel PA, Bekker P, Zhang Y, McDowell PJ, Johal J, Heaney LG, Murrell D, Stone MN, Yue H, Stone JH. Patel NJ, et al. Among authors: jayne drw. Lancet Rheumatol. 2023 Jul;5(7):e413-e421. doi: 10.1016/S2665-9913(23)00131-5. Lancet Rheumatol. 2023. PMID: 38251552 Clinical Trial.
The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials.
Bate S, McGovern D, Costigliolo F, Tan PG, Kratky V, Scott J, Chapman GB, Brown N, Floyd L, Brilland B, Martín-Nares E, Aydın MF, Ilyas D, Butt A, Nic An Riogh E, Kollar M, Lees JS, Yildiz A, Hinojosa-Azaola A, Dhaygude A, Roberts SA, Rosenberg A, Wiech T, Pusey CD, Jones RB, Jayne DRW, Bajema I, Jennette JC, Stevens KI, Augusto JF, Mejía-Vilet JM, Dhaun N, McAdoo SP, Tesar V, Little MA, Geetha D, Brix SR. Bate S, et al. Among authors: jayne drw. J Am Soc Nephrol. 2024 Mar 1;35(3):335-346. doi: 10.1681/ASN.0000000000000274. Epub 2023 Dec 12. J Am Soc Nephrol. 2024. PMID: 38082490
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
Hall FC, Cheriyan J, Cope AP, Galloway J, Wilkinson I, Bond S, Norton S, Banham-Hall E, Bayes H, Kostapanos M, Nodale M, Petchey WG, Sheeran T, Underwood J, Jayne DR; TACTIC-R Investigators Group. Hall FC, et al. Among authors: jayne dr. Lancet Respir Med. 2023 Dec;11(12):1064-1074. doi: 10.1016/S2213-2600(23)00376-4. Epub 2023 Nov 14. Lancet Respir Med. 2023. PMID: 37977159 Free PMC article. Clinical Trial.
227 results